Study on effect and mechanism of amiodarone combine with irbesartan on arrhythmia patients with heart failure
10.3969/j.issn.1671-8348.2016.01.020
- VernacularTitle:胺碘酮联合厄贝沙坦对心力衰竭合并心律失常的疗效及机制研究
- Author:
Haiping WU
;
Yahong ZHANG
;
Beibei WANG
- Publication Type:Journal Article
- Keywords:
amiodarone;
irbesartan;
heart failure;
arrhythmias,cardiac;
treatment outcome;
molecular mechanisms of pharma-cological action
- From:
Chongqing Medicine
2016;(1):59-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of amiodarone combine with irbesartan on arrhythmia patients with heart failure ,to observe its effect on cardiac function and its mechanism .Methods 124 patients with chronic heart failure combine with arrhythmia were selected in the hospital from September 2013 to November 2014 ,they were randomly divided into the control group and the observation group ,62 patients in each group .The control group was treated with amiodarone on the basis of routine thera-py ,the observation group was treated with amiodarone combine with irbesartan .The clinical efficacy of the two groups were as-sessed after treated 6 months ,the maintenance of sinus rhythm were observed after 1 ,3 and 6 months .By ultrasound heartbeat to assess heart function :cardiac stroke volume (SV) ,left ventricular ejection fraction (LVEF) ,left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) ,and to observe the adverse reactions .Results The efficiency rate of the observation group was 88 .71% (55/62) ,higher than that of the control group 62 .90% (39/62) ,the difference was statistically significant (P< 0 .05) .The maintenance rate of sinus rhythm after 1 ,3 and 6 months in observation group were 74 .19% (46/62) , 85 .48% (53/62) and 67 .74% (42/62) ,respectively ,higher than those of the control group[54 .84% (34/62) ,64 .52% (40/62) , 58 .06% (36/62)] ,the difference was statistically significant(P < 0 .05) .After treatment ,SV and LVEF of the observation group were (4 .69 ± 0 .31)L/min and (50 .31 ± 1 .20)% ,respectively ,higher than those of the control group (4 .22 ± 0 .30)L /min and (45 . 61 ± 0 .96)% ,SV and LVEF of two groups after treatment were higher than those of before treatment ,the difference was statisti-cally significant (P< 0 .05) .After treatment ,LVESD and LVEDD of the observation group were (51 .13 ± 3 .16)mm and (56 .20 ± 3 .24)mm ,respectively ,lower than those of the control group [(55 .08 ± 3 .03)mm and (60 .03 ± 3 .15)mm] ,LVESD and LVEDD of two groups after treatment were lower than those of before treatment ,the difference was statistically significant (P< 0 .05) .Com-pared the adverse reactions rate ,there was no statistically significant difference between the observation group and the control group (P> 0 .05) .Conclusion Amiodarone combine with irbesartan has good clinical efficacy in the treatment of heart failure combine with arrhythmia ,the maintenance rate of sinus rhythm can be significantly enhanced ,and improve heart function ,it has a higher se-curity .
